Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers

Cancer Immunology Immunotherapy(2022)10.1007/s00262-022-03205-5Source: DataRank Database

Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers is a research paper published in Cancer Immunology Immunotherapy (2022). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.98)OA: greenTopics (43)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Aki Furusawa ORCID,Ryuhei Okada ORCID,Fuyuki Inagaki ORCID,Takuya Kato ORCID,Hideyuki Furumoto ORCID

Live enrichment

PubMed:35445836 PMC:PMC10673684 OpenAlex:https://openalex.org/W4224242527

National Cancer Institute

Grant: ZIA BC011513

National Institutes of Health

Grant: 1ZIABC011513-04

Cancer-cell specific therapy: photo-immunotherapy

FWCI

0.98

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2026

greenLicense: Springer TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10673684/pdf/262_2022_Article_3205.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-022-03205-5.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-022-03205-5/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10673684

Fields of Study

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersImmune cells in cancer0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Immune Checkpoint ProteinsAnimalsEstersHumansImmunotherapyNeoplasmsXenograft Model Antitumor AssaysCell Line, TumorT-Lymphocytes, RegulatoryMice

Keywords

Cancer researchCancer immunotherapyTumor microenvironmentImmune systemImmunotherapyImmune checkpointT cellCancerCD8AntibodyMyeloid-derived Suppressor CellBiologyImmunologySuppressorRegulatory T Cell (Treg)Myeloid-derived Suppressor Cell (Mdsc)Near-infrared Photoimmunotherapy (Nir-pit)V-domain Immunoglobulin Suppressor Of T Cell Activation (Vista)EstersImmune Checkpoint ProteinsT-Lymphocytes, RegulatoryXenograft Model Antitumor AssaysMiceCell Line, TumorNeoplasmsHumansAnimals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being